Co-Authors
This is a "connection" page, showing publications co-authored by DIPEN MAHESHBHAI MARU and JEAN NICOLAS VAUTHEY.
Connection Strength
3.162
-
New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis. BJC Rep. 2024 Apr 26; 2(1):37.
Score: 0.240
-
New Insights into Macrophage Polarization and its Prognostic Role in Patients with Colorectal Cancer Liver Metastasis. Res Sq. 2023 Oct 19.
Score: 0.232
-
TP53 Alteration and Its Effect on Pathologic Response Are Associated with Survival after Resection of Colorectal Liver Metastases. J Gastrointest Surg. 2023 11; 27(11):2597-2600.
Score: 0.228
-
Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery. J Am Coll Surg. 2022 07 01; 235(1):8-16.
Score: 0.208
-
APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. Ann Surg. 2020 12; 272(6):1080-1085.
Score: 0.190
-
SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol. 2018 05; 44(5):684-692.
Score: 0.157
-
Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Ann Surg. 2018 03; 267(3):514-520.
Score: 0.157
-
Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017 02; 161(2):332-340.
Score: 0.141
-
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2016 08; 23(8):2635-43.
Score: 0.137
-
RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015 Mar; 22(3):834-842.
Score: 0.123
-
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol. 2014 Oct; 18(5):266-70.
Score: 0.122
-
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013 Oct; 258(4):619-26; discussion 626-7.
Score: 0.115
-
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013 Jun; 257(6):1079-88.
Score: 0.113
-
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012 Dec 20; 30(36):4566-72.
Score: 0.109
-
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
Score: 0.108
-
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
Score: 0.097
-
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010 Sep; 34(9):1287-94.
Score: 0.093
-
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010 Nov; 17(11):2870-6.
Score: 0.092
-
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009 Mar; 10(3):278-86.
Score: 0.084
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.082
-
Identification of Colorectal Cancer Cell Stemness from Single-Cell RNA Sequencing. Mol Cancer Res. 2024 04 02; 22(4):337-346.
Score: 0.060
-
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
Score: 0.049
-
Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102.
Score: 0.038
-
RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. 2017 01; 21(1):68-77.
Score: 0.035
-
Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015 Apr; 261(4):733-9.
Score: 0.032
-
Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer. 2013 Aug 01; 119(15):2778-88.
Score: 0.028
-
CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 2011 Dec; 197(6):W1060-6.
Score: 0.025
-
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
Score: 0.023
-
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009 Dec 02; 302(21):2338-44.
Score: 0.022
-
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
Score: 0.022